Villous atrophy that is not celiac disease: other causes doctors check
Short answer
Flat villi are a biopsy finding that celiac disease produces but does not own: Coeliac UK says villous atrophy is not specific to coeliac disease and is also seen with giardiasis, inflammatory conditions and certain medications1. A 2022 expert consensus on adults lists autoimmune enteropathy, common variable immunodeficiency, tropical sprue and giardiasis among the non-celiac enteropathies that are hard to tell from seronegative celiac disease, and drug-induced enteropathies among other causes of villous atrophy with negative serology2.
Part of Celiac diagnosis, testing and gluten sensitivity, 25 guides

Key points
- Coeliac UK describes villous atrophy as seen in untreated coeliac disease but not specific to it1.
- In one international cohort of 261 adults with non-celiac enteropathies, the most common causes were idiopathic villous atrophy (39%), drug related (17%), common variable immune deficiency (15%), infectious (10%) and autoimmune enteropathy (9%)3, 4.
- The Paris consensus calls medication-induced enteropathy the second most common cause of villous atrophy with negative celiac antibodies in adults, and one that can still be overlooked5.
- The consensus lists four criteria that must all be met to diagnose seronegative celiac disease, among them recovery on a gluten-free diet, exclusion of other causes and celiac-type HLA6.
- NIDDK says doctors do not recommend starting a gluten-free diet before diagnostic testing, because the diet can affect test results7.
Why flat villi are a finding, not a diagnosis
A 2025 review calls villous atrophy the primary histopathological lesion found in chronic enteropathies, and it names both celiac disease and non-celiac enteropathies as examples8.
The Oslo definitions, written by a task force of 16 physicians from seven countries9, define celiac disease as “a chronic small intestinal immune-mediated enteropathy precipitated by exposure to dietary gluten in genetically predisposed individuals”10. Gluten and genetics sit in that definition alongside the intestinal damage10.
The grades on a biopsy report do not change this. The same review says the Marsh-Oberhuber classification is not specific to celiac disease, because patterns resembling Marsh 3b and 3c lesions are seen in conditions such as autoimmune enteropathy and drug-induced enteropathy11.
Scope of the main source here: the Paris consensus covers chronic conditions in adults. It left out transient villous atrophy from acute gastroenteritis, which it says can lead to a flat mucosa that heals on its own, and it left out paediatric conditions12.
Which conditions do specialists list?
The Paris consensus was written by 13 gastroenterologists from six countries13. It sorted the chronic conditions that can cause villous atrophy with negative celiac antibodies into groups, shown below as the authors’ Table 1 lists them.
| Group in the consensus | Conditions it names |
|---|---|
| Celiac disease that presents with negative serology | Seronegative celiac disease; celiac disease with IgA deficiency; celiac disease with common variable immunodeficiency (CVID); dermatitis herpetiformis; a gluten-free diet or immunosuppressants already started2 |
| Non-celiac enteropathies that pose a problem in telling them from seronegative celiac disease | Autoimmune enteropathy; CVID; tropical sprue; giardiasis; indolent CD4+ T-cell lymphoma; idiopathic villous atrophy2 |
| Non-celiac enteropathies the consensus said pose less of a problem | Type 1 and type 2 enteropathy-associated T-cell lymphoma; Crohn’s disease; HIV enteropathy; iatrogenic enteropathies (drug-induced, transplanted small intestine, radiotherapy, graft-versus-host disease); eosinophilic enteritis2 |
| Conditions the consensus said not to consider as causes | Peptic duodenitis; NSAID enteropathy; Helicobacter pylori infection2 |
Seronegative celiac disease is part of the same differential. In adults it is the most common cause of villous atrophy with negative serology, yet the consensus says people with non-celiac enteropathies are frequently misdiagnosed as having it14, 15. Coeliac UK says research suggests seronegative disease accounts for around a third of patients with seronegative villous atrophy, and that it is important to rule out other causes of the gut damage16, 17.
How often each cause turns up depends on who is counted. In one international cohort of 261 adults with non-celiac enteropathies, followed up between 1992 and 2024, the most common etiologies were idiopathic villous atrophy (39%), drug related (17%), common variable immune deficiency (15%), infectious (10%) and autoimmune enteropathy (9%)3, 18, 4. That cohort left out patients with seronegative celiac disease and celiac disease with IgA deficiency19, so its percentages describe non-celiac causes only.
Medicines linked to celiac-like damage
The Paris consensus describes medication-induced enteropathy as the second most common cause of villous atrophy with negative celiac antibodies in adults, and one that can still be overlooked5.
One example is olmesartan (Benicar), an antihypertensive medicine20. Its prescribing information, as posted on DailyMed, has a section headed “Sprue-like Enteropathy”. It says severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan months to years after drug initiation, and that intestinal biopsies of these patients often demonstrated villous atrophy21. The label tells prescribers to exclude other etiologies when a patient develops these symptoms during treatment20.
A 2025 review says the biopsy picture of olmesartan-induced enteropathy, with shortened villi and more intraepithelial lymphocytes, overlaps significantly with celiac disease and can lead to diagnostic confusion22.
Olmesartan is not the only name on the lists. The Paris consensus names angiotensin II receptor blockers (particularly olmesartan), azathioprine, mycophenolate, methotrexate and chemotherapy as drug causes, and also lists transplanted small intestine, radiotherapy and graft-versus-host disease as iatrogenic causes2. The cohort study above, in its Methods, names angiotensin receptor blockers, immune checkpoint inhibitors, methotrexate, mycophenolate, azathioprine, colchicine and mefenamic acid as the culprit medications for the iatrogenic enteropathies it diagnosed23.
The sources disagree on NSAIDs. A 2025 review lists them among the drugs of most significant importance for non-celiac villous atrophy24. The Paris panel concluded, from its members’ clinical experience, that NSAID use, H. pylori infection and peptic duodenitis do not cause villous atrophy25. This page does not tell anyone to start, stop or change a medicine; that decision belongs to the prescriber.
Infections
Coeliac UK names giardiasis first among the other conditions that show villous atrophy1. The Paris consensus says that in a person with villous atrophy, negative celiac antibodies and malabsorption, giardiasis must be considered and thoroughly investigated26. It says confirming it needs at least one of these tests27:
- Giardia-specific stool antigens27
- Trophozoites identified on the duodenal biopsy specimens or on the duodenal aspirate27
- Cysts or trophozoites identified directly in fresh faeces27
- A Giardia-specific PCR27
Tropical sprue is another cause on the consensus list. The authors say to suspect it when malabsorption comes with a degree of villous atrophy (most often mild) and intraepithelial lymphocytosis, in someone with a history of living in or travelling to tropical countries for at least two months in poor hygienic conditions28.
In people with CVID, giardiasis and other gastrointestinal infections are major causes of the enteropathy, but the consensus notes that lesions can also occur with no apparent infection29. The 2025 review adds Cryptosporidium to the parasites that contribute30, and names Mycobacterium tuberculosis and Tropheryma whipplei among the bacterial causes31. It says confirming an infectious cause relies on pathogen identification, for example stool PCR testing32.
Immune conditions and other bowel diseases
Autoimmune enteropathy
The consensus calls autoimmune enteropathy a very rare enteropathy, described first in children and then in adults33. Its required criteria are severe malabsorption symptoms and frank villous atrophy that do not respond to any dietary restriction, enterocyte antibodies, negative celiac serology and exclusion of other causes34. The 2025 review says autoimmune enteropathy is marked by crypt destruction and apoptosis, which differ significantly from the crypt hyperplasia typical of celiac disease35.
Common variable immunodeficiency
The consensus counts CVID-associated enteropathy among the conditions that are hard to tell from seronegative celiac disease2. The review says CVID often lacks serological markers and overlaps histologically with other causes of villous atrophy, and that immunoglobulin profiling is instrumental for identifying the immune dysfunction in such cases36.
Idiopathic and lymphoma-related causes
Idiopathic villous atrophy is, in the consensus’s words, a very recently recognised and still poorly defined entity: frank villous atrophy unresponsive to a gluten-free diet, negative celiac serology, and all known causes thoroughly excluded37. The consensus also says small-bowel indolent CD4+ T-cell lymphoma is quite often mislabelled as type 2 refractory celiac disease, because villous atrophy and malabsorption persist despite a gluten-free diet38.
Conditions with clues of their own
For a group of other enteropathies the consensus gives the clinical clues and the test it associates with each39:
| Condition | Clinical clues listed | Test listed |
|---|---|---|
| Drug induced | Severe malabsorption, often with abrupt onset and a suggestive pharmacological history39 | Duodenal biopsy and drug withdrawal39 |
| Graft-versus-host disease | Severe malabsorption and a history of bone marrow transplantation39 | Duodenal biopsy39 |
| HIV enteropathy | Known history of AIDS, presence of opportunistic infections39 | HIV test39 |
| Eosinophilic gastroenteritis | History of atopy and allergies, after exclusion of parasites39 | Duodenal biopsy and peripheral hyper-eosinophilia39 |
| Crohn’s disease | Bloody diarrhoea, abdominal pain, fever, elevated CRP, ESR and faecal calprotectin39 | Colonoscopy with biopsy, duodenal biopsy, entero-MRI39 |
How antibodies, HLA and the biopsy history help tell them apart
Antibodies come first. The ACG guideline abstract calls detection of celiac-specific antibodies, such as tissue transglutaminase, very helpful for initial screening, and says an intestinal biopsy is required in most patients to confirm the diagnosis40. The Paris authors describe the adult diagnosis as villous atrophy plus positive celiac serology while on a gluten-containing diet41.
When the biopsy is flat and the antibodies are negative, the consensus lists what must be checked. Seronegative celiac disease needs exclusion of all other causes, meaning normal immunoglobulin levels, negative enterocyte antibodies, negative stool parasite, HIV and tuberculosis testing, no iatrogenic cause, and no history of travelling to or living in the tropics42.
HLA typing separates some of these. The consensus says it should always be performed in equivocal cases of villous atrophy with negative serology, and that a negative HLA typing excludes seronegative celiac disease. It adds that up to 30%–40% of people in Caucasian populations carry DQ2 or DQ843, 44. For some of the other conditions HLA typing has little or no role: it is irrelevant for diagnosing autoimmune enteropathy45, and for giardiasis the consensus says it has no relevance for the diagnosis but might be helpful in patients with borderline tTA to exclude celiac disease46. NIDDK states that having DQ2 or DQ8 alone does not mean a person has celiac disease47.
Serology can mislead in both directions. The consensus counts people who test negative because they are already on a gluten-free diet or immunosuppressive therapy as conventional celiac disease rather than seronegative disease48.
Pathologists and gastroenterologists read the biopsy together. The review says collaboration between them correlates the biopsy with clinical presentation, dietary history and serological outcomes49; the consensus starts by confirming there were no errors in sampling, collection or processing, such as incorrect orientation of duodenal specimens, and that the diet was not gluten restricted before endoscopy50.
Why a good diet response alone is not proof
Responding to a gluten-free diet counts as one criterion in the sources, not the whole test. The consensus says all of the following must be met to diagnose seronegative celiac disease, and celiac disease with IgA deficiency51: villous atrophy, crypt hyperplasia and more intraepithelial lymphocytes on correctly oriented specimens that recover on a gluten-free diet; diagnostic investigations done before a gluten-free diet or immunosuppressive therapy was started; exclusion of all other causes of villous atrophy; and HLA typing showing celiac haplotypes6. Coeliac UK’s list is similar: villous atrophy, compatible genetics, negative IgA tTG or IgG tTG, other causes excluded, and a clinical and histological response to the diet52.
Supportive features do not close the gap. The consensus says severe malabsorption, associated autoimmune disorders, a family history of celiac disease and biopsy-proven dermatitis herpetiformis can support the diagnosis but are not sufficient without the necessary criteria53. NIDDK likewise says celiac disease is not diagnosed from symptoms alone, because some symptoms resemble those of other digestive disorders54.
Starting the diet early also muddies the tests. NIDDK says doctors do not recommend starting a gluten-free diet before diagnostic testing because the diet can affect test results7, and Coeliac UK says patients need to be eating gluten during testing to obtain a reliable result55. In equivocal cases the consensus says reintroducing gluten can be necessary to bring back the intestinal lesions and symptoms and confirm the diagnosis56.
The mismatch runs the other way too. Non-celiac enteropathies of the “problem” group are described as villous atrophy that does not respond to a gluten-free diet57; the 2025 review says non-response to a gluten-free diet should prompt investigation of alternative causes, such as autoimmune or drug-induced enteropathy58. The ACG guideline defines nonresponsive celiac disease as persistent or recurrent symptoms despite the diet and calls for a systematic workup, especially for unintentional gluten contamination59.
The stakes are on both sides. The consensus says telling seronegative celiac disease from non-celiac enteropathies is key to avoid an unnecessary lifelong gluten-free diet and to treat disease-specific morbidity14. For people diagnosed with seronegative celiac disease, Coeliac UK says a follow-up biopsy may be considered after one to two years on the diet, or sooner in severe illness, to assess the response60.
Who runs the work-up and what it starts with
In the UK, Coeliac UK reports that NICE and BSG guidelines recommend referring people with a negative serological test to a gastrointestinal specialist for further assessment if celiac disease is still clinically suspected61.
The 2025 review says the differential diagnosis should first rely on quick and inexpensive methods, namely a thorough medical history including a detailed history of pharmacotherapy62.
Questions to bring to the gastroenterologist
These questions follow from the work-up items in the sources above. They are prompts for a conversation with the treating gastroenterologist, not medical advice, and nothing on this page suggests starting, stopping or changing a medicine or a diet.
- Were my celiac antibodies measured while I was eating gluten? NIDDK says the diet can affect test results7.
- Was the biopsy sampled and oriented so the villi could be judged reliably? The consensus names sampling and orientation errors as the first thing to rule out50.
- Was my medication list reviewed, including olmesartan and the other medicines named in the sources? The label for olmesartan describes villous atrophy on biopsy21; the consensus lists several other drug causes2.
- Were stool tests done for Giardia or other infections? The consensus says giardiasis must be considered and thoroughly investigated26.
- Were my immunoglobulin levels and other autoimmune markers checked? The consensus lists immunoglobulin levels and enterocyte antibodies among the exclusions42.
- Does my HLA typing fit celiac disease, and what would the result change? The consensus says a negative HLA typing excludes seronegative celiac disease44.
- If I improve on a gluten-free diet, which of the other criteria still need to be met before a diagnosis is made, and is a follow-up biopsy planned?6, 60
Questions people ask
Can flat villi be something other than celiac disease?
Yes. Coeliac UK says villous atrophy is not specific to coeliac disease and is seen in other conditions, including giardiasis, inflammatory conditions and certain medications1.
Can a medicine cause damage that looks like celiac disease?
The prescribing information for olmesartan reports severe, chronic diarrhea with weight loss and villous atrophy on biopsy in patients taking it, months to years after starting21. The Paris consensus includes angiotensin II receptor blockers, particularly olmesartan, among drug-induced enteropathies2.
Does a negative HLA result rule out celiac disease?
The Paris consensus says a negative HLA typing excludes seronegative celiac disease44. NIDDK says having DQ2 or DQ8 alone does not mean you have celiac disease, because most people with these gene variants do not develop it47.
How common is seronegative celiac disease among people with flat villi and negative antibodies?
Coeliac UK says research suggests it accounts for around a third of patients with seronegative villous atrophy16. The Paris consensus calls it the most common cause of villous atrophy with negative serology in adults14.
Do these lists apply to children?
The Paris consensus covered chronic conditions in adult patients and said paediatric conditions were outside its purposes12.
More in Celiac diagnosis, testing and gluten sensitivity
Reading a celiac biopsy report: Marsh grades and villous atrophyWhat villous atrophy, lymphocyte counts and Marsh 0 to 3c on a celiac biopsy report describe, and why guidelines read them with blood tests.
Marsh 1 on a biopsy report with negative celiac blood tests: what the guidelines sayWhat Marsh 1 or lymphocytic duodenosis means when celiac antibodies are negative, which other causes sources list, and what guidelines say comes next.
Celiac disease vs gluten intolerance: three conditions, three diagnosesHow celiac disease, non-celiac gluten sensitivity and wheat allergy differ in mechanism, diagnosis and diet, with a source behind every point.
Positive celiac blood test but a normal biopsy: what doctors call potential celiac diseaseWhat celiac guidelines say when antibodies are positive but the biopsy looks normal: potential celiac disease, other causes, and the follow-up described.
Seronegative celiac disease: when antibodies are negative but the biopsy is notWhat seronegative celiac disease means, which checks come before the label (total IgA, gluten intake, other causes) and what published series report.
Questions to bring to a gastroenterologist when celiac disease is suspectedQuestions for a celiac disease appointment: what to bring, what the sources say about diet before testing, and what to ask about the biopsy and follow-up.
All 25 guides in Celiac diagnosis, testing and gluten sensitivity
Related guides
HLA-DQ2 and HLA-DQ8 explained: the allele names on a celiac gene reportWhat DQA1, DQB1, DQ2.5, DQ2.2 and DQ8 mean on a celiac gene report, how often each appears in celiac disease, and how common they are overall.
Low total IgA and celiac disease: which tests guidelines name insteadWhy very low total IgA can hide celiac disease on the usual tTG-IgA test, which IgG-based tests guidelines name instead, and what a clinic should cover.
How a gluten challenge works before celiac testingWhat named celiac sources say about the amount and length of a gluten challenge before testing, side by side, and why a clinician plans it.
The repeat biopsy in celiac disease: when guidelines suggest one and what the result meansWhen guidelines suggest a repeat biopsy in celiac disease, what Marsh grades on the report mean, and what the guidelines say follows if damage persists.
Sources
- [1, 16, 52, 55, 60, 61] Coeliac UK, Seronegative coeliac disease (healthcare professionals), checked Nov 17, 2026.
Read on 2026-11-17: the list under “A diagnosis of seronegative can be made in patients with the following:” names presence of villous atrophy; genetics compatible with coeliac disease; negative immunoglobulin A (IgA) tissue transglutaminase (tTG), or IgG tTG; other causes of villous atrophy having been excluded; and clinical and histological response to the gluten free diet.
- [2, 5, 6, 12, 13, 14, 15, 25, 26, 27, 28, 29, 33, 34, 37, 38, 39, 41, 42, 43, 44, 45, 46, 48, 50, 51, 53, 56, 57] Europe PMC, Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus (Gut, 2022), checked Nov 17, 2026.
Read on 2026-11-17: Table 1, “List of enteropathies with villous atrophy and negative coeliac serology evaluated by the consensus group and divided into diagnostic categories”, has four columns. “Spectrum of CD presenting with negative serology” names seronegative CD; CD associated with IgA deficiency; CD associated with CVID; dermatitis herpetiformis; GFD already started; and immunosuppressants. “NCEs posing problems of differential diagnosis with seronegative forms of CD” names autoimmune enteropathy; CVID; tropical sprue; giardiasis; indolent CD4+ T cell lymphoma; and idiopathic villous atrophy. “NCEs not posing problems of differential diagnosis with seronegative forms of CD” names type 1 EATL; type 2 EATL; Crohn’s disease; HIV enteropathy; iatrogenic enteropathies; and eosinophilic enteritis. “Conditions not to consider as causes of villous atrophy” names peptic duodenitis; NSAIDs enteropathy; and Helicobacter pylori infection. The footnote on iatrogenic causes names drug-induced enteropathy (angiotensin II receptor blockers, particularly olmesartan, azathioprine, mycophenolate mofetil, methotrexate and chemotherapy), transplanted small intestine, radiotherapy and graft-versus-host disease.
Read on 2026-11-17: the list under “The following criteria must be satisfied to make a diagnosis of both seronegative CD and CD associated to IgA deficiency:” has four items: VA, crypt hyperplasia and an increased intraepithelial lymphocytes count on correctly oriented duodenal specimens, recovering on a GFD; performing diagnostic investigations before starting a GFD or immunosuppressive therapy; exclusion of all the other causes of VA; and evidence of HLA typing showing specific coeliac haplotypes (DQ2.5, DQ8, DQ2.2 or DQ7.5).
Read on 2026-11-17: the list under “In order to confirm the diagnosis, at least one of these tests is necessary:” names positive Giardia specific stool antigens; identification of trophozoites on formalin-fixed paraffin-embedded H&E stained duodenal specimens and/or on the duodenal aspirate; direct identification of cysts/trophozoites in fresh faeces; and specific Giardia PCR.
Read on 2026-11-17: the list under “the following criteria must be satisfied for the diagnosis of autoimmune enteropathy” names severe malabsorption symptoms (chronic diarrhoea, weight loss, nutritional deficiencies and electrolyte imbalance) unresponsive to any dietary restriction; frank VA unresponsive to any dietary restriction; IgA/IgG positive enterocyte antibodies; negative coeliac serology; and exclusion of other causes of VA.
Read on 2026-11-17: Table 2, “Clinical clues guiding the diagnosis of enteropathies not posing problems of differential diagnosis with seronegative coeliac disease”, gives clinical and laboratory features, duodenal biopsy features and diagnostic tests for EATL, drug induced, chemotherapy, radiotherapy, GVHD, HIV enteropathy, eosinophilic gastroenteritis and Crohn’s disease. The drug induced row reads “Severe malabsorption, often with abrupt onset and suggestive pharmacological history” with the test “Duodenal biopsy and drug withdrawal”; the GVHD row “Severe malabsorption and history of bone marrow transplantation” with “Duodenal biopsy”; the HIV enteropathy row “Known history of AIDS, presence of opportunistic infections” with “HIV test”; the eosinophilic gastroenteritis row “History of atopy and allergies, after exclusion of parasites” with “Duodenal biopsy and peripheral hyper-eosinophilia”; the Crohn’s disease row “Bloody diarrhoea, abdominal pain, fever, elevated CRP, ESR and faecal calprotectin” with “Colonoscopy+biopsy, duodenal biopsy, entero-MRI”.
- [3, 4, 18, 19, 23] Europe PMC, Long-term Prognosis of Nonceliac Enteropathies and a Score to Identify Patients With Poor Outcomes (Am J Gastroenterol, 2025), checked Nov 17, 2026.
Read on 2026-11-17: the Methods sentence on iatrogenic enteropathies names, as culprit medications, ARBs, immune checkpoint inhibitors, methotrexate, mycophenolate, azathioprine, colchicine and mefenamic acid.
- [7, 47, 54] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Diagnosis of Celiac Disease, checked Nov 17, 2026.
- [8, 11, 22, 24, 30, 31, 32, 35, 36, 49, 58, 62] Europe PMC, Non-Celiac Villous Atrophy: A Problem Still Underestimated (Life, 2025 review), checked Nov 17, 2026.
- [9, 10] PubMed (US National Library of Medicine), The Oslo definitions for coeliac disease and related terms (Gut, 2013), abstract, checked Nov 17, 2026.
- [17] Coeliac UK, Testing for coeliac disease: blood tests and biopsy, checked Nov 17, 2026.
- [20, 21] DailyMed (US National Library of Medicine), Cosette Pharmaceuticals, Benicar (olmesartan medoxomil) prescribing information, checked Nov 17, 2026.
- [40, 59] PubMed (US National Library of Medicine), ACG Guidelines Update: Diagnosis and Management of Celiac Disease (Am J Gastroenterol, 2023), abstract, checked Nov 17, 2026.